
Residuals of Model 4
A
B
Predicted HbA1c (mmol/mol)
Observed HbA1c (mmol/mol)
Standardised Residuals
Average Predicted HbA1c (mmol/mol)
160
120
80
40
5.0
2.5
0.0
−2.5
−5.0
60
100


R2 (bigger is better)
Model
0.26
0.28
0.30
0.32
RMSE (smaller is better)
Model
13.4
13.6
13.8
RSS (smaller is better)
Model
1300000
1400000
1500000
1600000
1700000
Model
Dataset
Development
Validation

Effect submodels






A
B
Favours GLP1
Favours SGLT2
Number of people
HbA1c difference (mmol/mol)
0
300
600
900
200
400
800
−10
0
10
20


A
Male
Favours GLP1
Favours SGLT2
Number of people
1000
750
500
250
0
−10
0
10
20
HbA1c difference (mmol/mol)
Female
Favours GLP1
Favours SGLT2
Number of people
600
400
200
0
−10
0
10
20
HbA1c difference (mmol/mol)
B
Male
Favours GLP1
Favours SGLT2
Number of people
600
400
200
0
−10
0
10
20
HbA1c difference (mmol/mol)
Female
Favours GLP1
Favours SGLT2
Number of people
400
300
200
100
0
−10
0
10
20
HbA1c difference (mmol/mol)


Effects validation lm(hba1c~drugclass+prop_score)
A
B
Decile average treatment effect
Predicted conditional average treatment effec
14
12
10
8
6
4
2
0
−2
−4
−6
−8
−10
−12
−14

Effects validation prop score matching



Effects validation prop score inverse weighting